Synthesis and Antitumor Molecular Mechanism of Agents Based on Amino 2-(3',4',5'-Trimethoxybenzoyl)benzo[b]furan: Inhibition of Tubulin and Induction of Apoptosis

ChemMedChem

Volumn 6, Issue 10, 2011, Pages 1841-1853

  Romagnoli, Romeo ^a   Baraldi, Pier Giovanni ^a   Lopez Cara, Carlota ^a   Cruz Lopez, Olga ^a   Carrion, Maria Dora ^a   KimatraiSalvador, Maria ^a   Bermejo, Jaime ^b   Estévez, Sara ^c   Estévez, Francisco ^c   Balzarini, Jan ^d   Brancale, Andrea ^e   Ricci, Antonio ^e   Chen, Longchuan ^f   Kim, Jae Gwan ^g   Hamel, Ernest ^h  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^g Gwangju Institute of Science and Technology (GIST)   (South Korea)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antiproliferative agents; Apoptosis; Caspase activation; Colchicine binding site; Tubulin

Indexed keywords

(4 AMINOBENZO[B]FURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (5 AMINO 3 METHYL 6 METHOXYBENZO[B]FURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (5 AMINO 3 METHYL 7 METHOXYBENZO[B]FURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (5 AMINO 3 METHYLBENZO[B]FURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (5 AMINO 6 METHOXYBENZO[B]FURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (5 AMINO 7 METHOXYBENZO[B]FURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (5 AMINOBENZO[B]FURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (6 AMINOBENZO[B]FURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (7 AMINO 3 METHYL 5 METHOXYBENZO[B]FURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (7 AMINOBENZO[B]FURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; 2 (3',4',5' TRIMETHOXYBENZOYL) 3 METHYL 5 AMINO 6 METHOXYBENZO[B]FURAN; 2 (3',4',5' TRIMETHOXYBENZOYL)BENZO[B]FURAN DERIVATIVE; 2 BROMO N [2 (3,4,5 TRIMETHOXYBENZOYL) 1 BENZO[B]FURAN 4 YL]ACRYLAMIDE; 2 BROMO N [2 (3,4,5 TRIMETHOXYBENZOYL) 1 BENZO[B]FURAN 5 YL]ACRYLAMIDE; 2 BROMO N [2 (3,4,5 TRIMETHOXYBENZOYL) 1 BENZO[B]FURAN 6 YL]ACRYLAMIDE; 2 BROMO N [2 (3,4,5 TRIMETHOXYBENZOYL) 1 BENZO[B]FURAN 7 YL]ACRYLAMIDE; 2 BROMO N [3 METHYL 2 (3,4,5 TRIMETHOXYBENZOYL) 1 BENZO[B]FURAN 5 YL]ACRYLAMIDE; 2 BROMO N [3 METHYL 5 METHOXY 2 (3,4,5 TRIMETHOXYBENZOYL) 1 BENZO[B]FURAN 7 YL]ACRYLAMIDE; 2 BROMO N [3 METHYL 6 METHOXY 2 (3,4,5 TRIMETHOXYBENZOYL) 1 BENZO[B]FURAN 5 YL]ACRYLAMIDE; 2 BROMO N [3 METHYL 7 METHOXY 2 (3,4,5 TRIMETHOXYBENZOYL) 1 BENZO[B]FURAN 5 YL]ACRYLAMIDE; 2 BROMO N [7 METHOXY 2 (3,4,5 TRIMETHOXYBENZOYL) 1 BENZO[B] FURAN 5 YL]ACRYLAMIDE; 4 BUTYL [2 [[6 METHOXY 3 METHYL 2 (3,4,5 TRIMETHOXYBENZOYL) 1 BENZO[B]FURAN 5 YL]AMINO] 2 OXOETHYL]CARBAMATE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; COLCHICINE; COMBRETASTATIN A4; N [6 METHOXY 3 METHYL 2 (3,4,5 TRIMETHOXYBENZOYL) 1 BENZO[B] FURAN 5 YL]GLYCINAMIDE HYDROCHLORIDE; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; MITOCHONDRION; PRIORITY JOURNAL; SUBSTITUTION REACTION;

ANIMALS; ANISOLES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOFURANS; BINDING SITES; CASPASES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; COLCHICINE; HUMANS; MICE; NEOPLASMS; TUBULIN; TUBULIN MODULATORS;

EID: 80053398841     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201100279     Document Type: Article

References (59)

1. C. B. Thompson, Science 1995, 267, 1456-1462.
2. J. C. Reed, Nat. Rev. Drug Discovery 2002, 1, 111-121.
3. I. M. Ghobrial, T. E. Witzig, A. A. Adjei, CA Cancer J. Clin. 2005, 5, 178-194.
4. A. L. Risinger, F. J. Giles, S. L. Mooberry, Cancer Treat. Rev. 2009, 35, 255-261;
5. R. O. Carlson, Expert Opin. Invest. Drugs 2008, 17, 707-722.
6. C. E. Walczak, Curr. Opin. Cell Biol. 2000, 12, 52-56;
7. S. Honore, E. Pasquier, D. Braguer, Cell. Mol. Life Sci. 2005, 62, 3039-3056.
8. G. R. Pettit, S. B. Singh, E. Hamel, C. M. Lin, D. S. Alberts, D. Garcia-Kendall, Experientia 1989, 45, 209-211.
9. C. M. Lin, H. H. Ho, G. R. Pettit, E. Hamel, Biochemistry 1989, 28, 6984-6991.
10. D. M. Patterson, G. J. S. Rustin, Drugs Future 2007, 32, 1025-1032.
11. G. C. Tron, T. Pirali, S. Sorba, F. Pagliai, S. Busacca, A. A. Genazzani, J. Med. Chem. 2006, 49, 3033-3044;
12. N. Mahindroo, J. P. Liou, J. Y. Chang, H. P. Hsieh, Expert Opin. Ther. Pat. 2006, 16, 647-691;
13. M. A. Jordan, L. Wilson, Nat. Rev. Cancer 2004, 4, 253-265;
14. A. Chaudhary, S. N. Pandeya, P. Kumar, P. P. Sharma, S. Gupta, N. Soni, K. K. Verma, G. Bhardwaj, Mini Rev. Med. Chem. 2007, 7, 1186-1205;
15. H. P. Hsieh, J. P. Liou, N. Mahindroo, Curr. Pharm. Des. 2005, 11, 1655-1677.
16. T. Hatanaka, K. Fujita, K. Ohsumi, R. Nakagawa, Y. Fukuda, Y. Nihei, Y. Suga, Y. Akiyama, T. Tsuji, Bioorg. Med. Chem. Lett. 1998, 8, 3371-3374;
17. K. Ohsumi, R. Nakagawa, Y. Fukuda, T. Hatamaka, Y. Morinaga, Y. Nihei, K. Ohishi, Y. Suga, Y. Akiyama, T. Tsuji, J. Med. Chem. 1998, 41, 3022-3032.
18. A. Delmonte, C. Sessa, Exp. Opin. Invest. Drugs 2009, 18, 1541-1548:
19. D. W. Siemann, D. J. Chaplin, P. Walike, Expert Opin. Invest. Drugs 2009, 18, 189-197.
20. K. Hori, S. Saito, Br. J. Cancer 2003, 89, 1334-1344;
21. K. Hori, S. Saito, Br. J. Cancer 2004, 90, 549-53.
22. R. Romagnoli, P. G. Baraldi, T. Sarkar, M. D. Carrion, O. Cruz-Lopez, C. Lopez-Cara, M. Tolomeo, S. Grimaudo, A. DiCristina, M. R. Pipitone, J. Balzarini, R. Gambari, L. Ilaria, R. Saletti, A. Brancale, E. Hamel, Bioorg. Med. Chem. 2008, 16, 8419-8426.
23. K. Gaukroger, J. A. Hadfield, N. J. Lawrence, S. Nlan, A. T. McGown, Org. Biomol. Chem. 2003, 1, 3033-3037.
24. I. Beria, P. G. Baraldi, P. Cozzi, M. Caldarelli, C. Geroni, S. Marchini, N. Mongelli, R. Romagnoli, J. Med. Chem. 2004, 47, 2611-2623.
25. R. Romagnoli, P. G. Baraldi, O. Cruz-Lopez, C. Lopez-Cara, D, Preti, Mini-Rev. Med. Chem. 2009, 9, 81-94.
26. N. H. Nam, Y. Kim, Y. J. Yu, D. H. Hong, H. M. Kim, B. Z. Ahn, Bioorg. Med. Chem. 2003, 11, 1021-1029;
27. G. R. Pettit, C. R. Anderson, D. L. Herald, M. K. Jung, D. J. Lee, E. Hamel, R. K. Pettit, J. Med. Chem. 2003, 46, 525-531.
28. 2-Hydroxy-3-nitrobenzaldehyde (6e), 2-hydroxy-5-nitrobenzaldehyde (6b), and 1-(2-hydroxy-5-nitrophenyl)ethanone (6c) are commercially available and were used as received; 2-hydroxy-6-nitrobenzaldehyde
29. 6a) was prepared by following the procedure reported here: L. P. Miranda, W. D. F. Meutermans, M. L. Smythe, P. F. Alewood, J. Org. Chem. 2000, 65, 5460- 5468
30. For the preparation of 6d, see: K. S. MacMillan, T. Nguyen, I. Hwang, D. L. Boger, J. Am. Chem. Soc. 2009, 131, 1187- 1194. For the preparation of 1-(2-hydroxy-5-methoxy-3-nitrophenyl)ethanone
31. (6 f), see M. Cushman, H. Zhu, R. L. Geahlen, A. J. Kraker, J. Med. Chem. 1994, 37, 3353 -3362. For the synthesis of 2-hydroxy-4-methoxy-5-nitrobenzaldehyde
32. (6g), see: M. Guru, S. Rao, C. Srikantia, M. S. Iyengar, J. Chem. Soc. 1924, 556- 560
33. For the preparation of 1-(2-hydroxy-4-methoxy-5-nitrophenyl)ethanone (6h), see: H. Banks, J. Am. Chem. Soc. 1938, 60, 1370
34. For the synthesis of 2-hydroxy-3-methoxy-5-nitrobenzaldehyde (6i), see: M. Kowalewska, H. Kwiecień , Tetrahedron 2008, 64, 5085 -5090
35. For the synthesis of 1-(2-hydroxy-3-methoxy-5-nitrophenyl) ethanone (6j), see: W. Horton, J. T. Spence, J. Am. Chem. Soc. 1958, 80, 2453 -2456.
36. E. Hamel, Cell Biochem. Biophys. 2003, 38, 1-21;
37. P. Verdier-Pinard, J.-Y. Lai, H.-D. Yoo, J. Yu, B. Marquez, D. G. Nagle, M. Nambu, J. D. White, J. R. Falck, W. H. Gerwick, B. W. Day, E. Hamel, Mol. Pharmacol. 1998, 53, 62-76.
38. S. Rello, J. Stockert, V. Moreno, A. Gamez, M. Pacheco, A. Juarranz, M. Canete, A. Villanueva, Apoptosis 2005, 10, 201-208.
39. H. Steller, Science 1995, 267, 1445-1449.
40. T. Q. Nhan, W. C. Liles, S. M. Scwartz, Am. J. Pathol. 2006, 169, 729-737;
41. D. Graf, J. G. Bode, D. Haussinger, Arch. Biochem. Biophys. 2007, 462, 162-170.
42. S. A. Susin, H. K. Lorenzo, N. Zamzami, I. Marzo, C. Brenner, N. Larochette, M. C. Prevost, P. M. Alzari, G. Kroemer, J. Exp. Med. 1999, 189, 381-394;
43. J.-B. Denault, G. S. Salvesen, Chem. Rev. 2002, 102, 4489-4499.
44. C. Soldani, A. I. Scovassi, Apoptosis 2002, 7, 321-328.
45. K. Ratnam, J. A. Low, Clin. Cancer Res. 2007, 13, 1383-1388.
46. C. M. Knudson, S. J. Korsmeyer, Nature Genet. 1997, 16, 358-363.
47. X. Jiang, X. Wang, Annu. Rev. Biochem. 2004, 73, 87-106;
48. R. M. Kluck, E. Bossy-Wetzel, D. R. Green, D. D. Newmeyer Science 1997, 275, 1132-1136.
49. L. Vincent, P. Kermani, L. M. Young, J. Cheng, F. Zhang, K. Shido, G. Lam, H. Bompais-Vincent, Z. Zhu, D. J. Hicklin, P. Bohlen, D. J. Chaplin, C. May, S. Rafii, J. Clin. Invest. 2005, 115, 2992-3006.
50. D. J. Cuccia, F. Bevilacqua, A. J. Durkin, B. Tromberg, J. Opt. Lett. 2005, 30, 1354-1356;
51. D. J. Cuccia, F, Bevilacqua, A. J. Durkin, F. R. Ayers, B. J. Tromberg, J. Biomed. Opt. 2009, 14, 024012.
52. K. Brindle, Nature Rev. Cancer 2008, 8, 94-107.
53. E. Hamel, C. M. Lin, Biochemistry 1984, 23, 4173-4184.
54. S. Rubio, J. Quintana, J. L. Eiroa, J. Triana, F. Estévez, Carcinogenesis 2007, 28, 2105-2013.
55. M. M. Bradford, Anal. Biochem. 1976, 72, 248-254.
56. T. A. Erickson, A. Mazhar, A. Cuccia, J. Durkin, J. W. Tunnel, J. Biom. Opt. 2010, 15, 036013.
57. R. B. G. Ravelli, B. Gigant, P. A. Curmi, I. Jourdain, S. Lachkar, A. Sobel, M. Knossow, Nature 2004, 428, 198-202.
58. Molecular Operating Environment (MOE 2010.10), Chemical Computing Group Inc., Montreal, QC (Canada): (accessed July 6, 2011).
59. O. Korb, T. Stützle, T.E. Exner, "PLANTS: Application of Ant Colony Optimization to Structure-Based Drug Design", in Ant Colony Optimization and Swarm Intelligence, 5th International Workshop, ANTS 2006, Brussels (Belgium), September 4-7, 2006 (Eds.: M. Dorigo, L.M. Gambardella, M. Birattari, A. Martinoli, R. Poli, T. Stützle), Springer, Berlin, 2006, LNCS 4150, pp.247-258.